Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 33.57 -5.57% -1.98
GTHX closed down 5.57 percent on Friday, September 20, 2019, on 2.07 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical GTHX trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.57%
Narrow Range Bar Range Contraction -5.57%
NR7 Range Contraction -5.57%
NR7-2 Range Contraction -5.57%
Inside Day Range Contraction -5.57%
Fell Below 20 DMA Bearish -5.57%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.57%

Older signals for GTHX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Hormones Astrazeneca Protein Kinase Inhibitors Treatment Of Breast Cancer Her2/Neu Antiestrogens
Is GTHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 60.0
52 Week Low 13.87
Average Volume 355,130
200-Day Moving Average 23.9259
50-Day Moving Average 31.9774
20-Day Moving Average 36.2615
10-Day Moving Average 37.243
Average True Range 2.7214
ADX 18.08
+DI 17.0232
-DI 21.9891
Chandelier Exit (Long, 3 ATRs ) 33.6358
Chandelier Exit (Short, 3 ATRs ) 40.0142
Upper Bollinger Band 40.2623
Lower Bollinger Band 32.2607
Percent B (%b) 0.16
BandWidth 22.066379
MACD Line 0.9012
MACD Signal Line 1.597
MACD Histogram -0.6958
Fundamentals Value
Market Cap 949.53 Million
Num Shares 28.3 Million
EPS -11.02
Price-to-Earnings (P/E) Ratio -3.05
Price-to-Sales 0.00
Price-to-Book 4.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.55
Resistance 3 (R3) 37.81 36.73 36.89
Resistance 2 (R2) 36.73 35.72 36.60 36.67
Resistance 1 (R1) 35.15 35.09 34.61 34.90 36.45
Pivot Point 34.08 34.08 33.81 33.95 34.08
Support 1 (S1) 32.50 33.06 31.96 32.24 30.69
Support 2 (S2) 31.42 32.43 31.29 30.47
Support 3 (S3) 29.84 31.42 30.25
Support 4 (S4) 29.59